EGFR TKIs, gefitinib [1], erlotinib [2], and afatinib [3], and ALK inhibitors, crizotinib [4] and ceritinib [5], have prolonged progression-free survival (PFS) rates in advanced lung adenocarcinoma patients with sensitive EGFR mutations and ALK rearrangement, respectively. The gene discussed is ALK; the disease is lung adenocarcinoma.